Abstract
Vasculopathy in patients with connective tissue diseases (CTDs), including systemic sclerosis (SSc) and systemic lupus erythematosus (SLE), is a serious complication that mainly affects small arteries and capillaries, reduces the blood flow and causes progressive tissue ischemia. Recently, CTD patients have been reported to have abnormalities in circulating endothelial progenitor cells (EPCs); these abnormalities are believed to contribute to the pathophysiology of vasculopathy and to the premature and accelerated development of atherosclerosis in CTD patients. Furthermore, we are currently conducting a clinical pilot study to determine the efficacy of implanting autologous mononuclear cells obtained from the bone marrow and peripheral blood into the ischemic digits or limbs of CTD patients. In this review, we discuss the role of EPCs in the process of neovascularization and in the pathophysiology of CTDs, and we describe a clinical pilot study on the use of autologous cell therapy for treating ischemic digits in patients with CTDs.
Keywords: Angiogenesis, mononuclear cells, connective tissue disease, EPCs, ischemia, scleroderma, vasculopathy
Current Pharmaceutical Design
Title: Therapeutic Neovascularization by the Implantation of Autologous Mononuclear Cells in Patients with Connective Tissue Diseases
Volume: 15 Issue: 24
Author(s): Masafumi Takahashi, Atsushi Izawa, Yoshiaki Ishigatsubo, Kazuteru Fujimoto, Masaaki Miyamoto, Takashi Horie, Yoshifusa Aizawa, Jun Amano, Seiji Minota, Toyoaki Murohara, Hiroaki Matsubara and Uichi Ikeda
Affiliation:
Keywords: Angiogenesis, mononuclear cells, connective tissue disease, EPCs, ischemia, scleroderma, vasculopathy
Abstract: Vasculopathy in patients with connective tissue diseases (CTDs), including systemic sclerosis (SSc) and systemic lupus erythematosus (SLE), is a serious complication that mainly affects small arteries and capillaries, reduces the blood flow and causes progressive tissue ischemia. Recently, CTD patients have been reported to have abnormalities in circulating endothelial progenitor cells (EPCs); these abnormalities are believed to contribute to the pathophysiology of vasculopathy and to the premature and accelerated development of atherosclerosis in CTD patients. Furthermore, we are currently conducting a clinical pilot study to determine the efficacy of implanting autologous mononuclear cells obtained from the bone marrow and peripheral blood into the ischemic digits or limbs of CTD patients. In this review, we discuss the role of EPCs in the process of neovascularization and in the pathophysiology of CTDs, and we describe a clinical pilot study on the use of autologous cell therapy for treating ischemic digits in patients with CTDs.
Export Options
About this article
Cite this article as:
Takahashi Masafumi, Izawa Atsushi, Ishigatsubo Yoshiaki, Fujimoto Kazuteru, Miyamoto Masaaki, Horie Takashi, Aizawa Yoshifusa, Amano Jun, Minota Seiji, Murohara Toyoaki, Matsubara Hiroaki and Ikeda Uichi, Therapeutic Neovascularization by the Implantation of Autologous Mononuclear Cells in Patients with Connective Tissue Diseases, Current Pharmaceutical Design 2009; 15 (24) . https://dx.doi.org/10.2174/138161209788923813
DOI https://dx.doi.org/10.2174/138161209788923813 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Mechanism of Calcitriol in Cancer Prevention and Treatment
Current Medicinal Chemistry Diabetic Cardiomyopathy and Oxidative Stress: Role of Antioxidants
Cardiovascular & Hematological Agents in Medicinal Chemistry 10 Years of SELDI: What Have we Learnt?
Current Proteomics Post-stroke Depression Therapy: Where are we now?
Current Neurovascular Research An Overview of the Design, Development and Applications of Biodegradable Stents
Drug Delivery Letters Preclinical Pharmacokinetics, Pharmacodynamics and Safety of Sucroferric Oxyhydroxide
Current Drug Metabolism Editorial (Thematic Issue: New Therapeutic Targets in Clinical Medicine)
Current Pharmaceutical Design Nitric Oxide Production and Signaling in Inflammation
Current Drug Targets - Inflammation & Allergy Current Understanding of Dietary Polyphenols and their Role in Health and Disease
Current Nutrition & Food Science Assessment and Clinical Relevance of Non-Fasting and Postprandial Triglycerides: An Expert Panel Statement
Current Vascular Pharmacology The Effect of Antihypertensive Drugs on Central Blood Pressure Beyond Peripheral Blood Pressure. Part II: Evidence for Specific Class-Effects of Antihypertensive Drugs on Pressure Amplification
Current Pharmaceutical Design Metabolomics Analysis for Biomarker Discovery: Advances and Challenges
Current Medicinal Chemistry Green Synthesis of Novel Phthalimide Derivatives of Aspirin and P-aminosalicylic Acid as Potential Analgesic- antipyretic and Anti-tuberculosis Agents
Letters in Organic Chemistry Low-dose Computed Tomography (CT) for the Diagnosis of Congenital Heart Disease in Children: A Meta-analysis
Current Medical Imaging The Role of Interleukin-18 in the Development and Progression of Atherosclerosis
Current Medicinal Chemistry Future Therapeutic Strategies in Inflammatory Cardiomyopathy: Insights from the Experimental Autoimmune Myocarditis Model
Cardiovascular & Hematological Disorders-Drug Targets Physiological Significance and Therapeutic Potential of Adrenomedullin in Pulmonary Hypertension
Cardiovascular & Hematological Disorders-Drug Targets Treating Older HIV-1-infected Subjects With Cobicistat-boosted Darunavir in a 48-week Phase 3 Trial
Reviews on Recent Clinical Trials Polypharmacy in Cardiovascular Medicine: Problems and Promises!
Cardiovascular & Hematological Agents in Medicinal Chemistry Nutrigenetics, Metabolic Syndrome Risk and Personalized Nutrition
Current Vascular Pharmacology